Cepheid Nabs CE-IVD Mark for Molecular NPM1 Mutation Test for AML Monitoring
The test quantifies mutant NPM1 mRNA transcripts in peripheral blood specimens from patients with acute myeloid leukemia.
Geneseeq Nabs CE Marks for Residual Disease and Cancer Early Detection Tests
The MRD assay uses deep sequencing to detect cancer mutations in blood post-surgery and the early detection test involves multiomic analysis of cell-free DNA.
SeekIn Receives CE-IVD Mark for Leukemia Cancer Mutation Detection Kit
The company's PanCanSeek test uses whole-genome sequencing to analyze bone marrow samples from leukemia patients, replacing a variety of more targeted technologies.
SeekIn Receives CE-IVD Mark for Cancer Recurrence Monitoring Test
The company's SeekInCure pan-cancer assay detects minimal residual disease in patient blood samples and has been validated in hepatocellular carcinoma.
Genetika+ Snags CE Mark for Major Depressive Disorder Drug-Matching Test
The NeuroKaire test predicts a patient's drug response by combining patient-reported information, pharmacogenetics data, and so-called "brain-in-a-dish" functional testing.